250 related articles for article (PubMed ID: 20670166)
1. Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Mokhtar GM; Matter RM; Shawki H; Abdel Aziz MM
Pediatr Hematol Oncol; 2010 Aug; 27(5):363-73. PubMed ID: 20670166
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic alterations in splenectomized and non-splenectomized patients with beta-thalassemia/hemoglobin E disease.
Tripatara A; Jetsrisuparb A; Teeratakulpisarn J; Kuaha K
Thromb Res; 2007; 120(6):805-10. PubMed ID: 17382994
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
4. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
Sonmez M; Aydin K; Durmus A; Sucu N; Yilmaz M; Akdogan E; Koksal I; Ovali E; Omay SB
J Infect; 2007 Aug; 55(2):184-7. PubMed ID: 17418898
[TBL] [Abstract][Full Text] [Related]
5. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
Chhikara A; Sharma S; Chandra J; Nangia A
Indian J Pediatr; 2017 Jan; 84(1):25-30. PubMed ID: 27487812
[TBL] [Abstract][Full Text] [Related]
6. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
8. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
9. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
10. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
[TBL] [Abstract][Full Text] [Related]
11. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
Balcik OS; Albayrak M; Uyar ME; Dagdas S; Yokus O; Ceran F; Cipil H; Kosar A; Ozet G
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):260-3. PubMed ID: 21297448
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
13. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
14. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
Rooth E; Wallen H; Antovic A; von Arbin M; Kaponides G; Wahlgren N; Blombäck M; Antovic J
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):365-70. PubMed ID: 17473579
[TBL] [Abstract][Full Text] [Related]
15. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Van Thiel DH; George M; Fareed J
Thromb Haemost; 2001 Apr; 85(4):667-70. PubMed ID: 11341503
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease.
Angchaisuksiri P; Atichartakarn V; Aryurachai K; Archararit N; Chuncharunee S; Tiraganjana A; Rattanasiri S
Am J Hematol; 2007 Nov; 82(11):1001-4. PubMed ID: 17654509
[TBL] [Abstract][Full Text] [Related]
19. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
20. Tricuspid regurgitation in patients with beta-thalassemia major.
Wu KH; Chang JS; Su BH; Peng CT
Ann Hematol; 2004 Dec; 83(12):779-83. PubMed ID: 15449031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
